Strides secures shareholders approval for OneSource CDMO
The company will now seek final approval from NCLT, Mumbai Bench, and upon its receipt, OneSource will proceed to seek listing approvals from the BSE and NSE
The company will now seek final approval from NCLT, Mumbai Bench, and upon its receipt, OneSource will proceed to seek listing approvals from the BSE and NSE
A new initiative to contribute to enhancing drug discovery capabilities in the field of gene and cell therapy in Japan
e brings over 27+ years of rich pharmaceutical experience
Abdel has held leadership positions at Bayer, Merck, Catalent, Lonza, and KBI Biopharma,
Sapala has a strong customer base including innovator Pharma, CDMOs & diagnostic companies
Additional capacity broadens Grace’s fine chemical capabilities for API production
BHL will undertake the development and supply of these molecules
Glenmark Life Sciences will manufacture API in the therapeutic area of urinary anti-spasmodic, to supply to the global innovator
Development services for gene and cell therapies is planned to begin first in 2025
Subscribe To Our Newsletter & Stay Updated